Morphic Medical Strengthens Senior Team with Appointment of Jane Wright as Chief Financial Officer

London, 11 September 2025 – Morphic Medical, creator of RESET® – the first, endoscopic non-surgical treatment for both obesity and type 2 diabetes in Europe – is pleased to announce the appointment of Jane Wright as its Chief Financial Officer.

Jane is a qualified accountant with over 30 years of experience including several senior financial and operational positions in international medical device companies, navigating complex regulatory environments and driving strategic growth and operational efficiency.

Prior to joining Morphic Medical, she served as Finance & Operations Director at Apollo Endosurgery, a specialist in endoluminal surgery (ELS) procedures which was acquired by Boston Scientific Corporation in 2022.

Jane’s arrival follows the appointment of Mike Gutteridge as Chief Executive Officer in July and marks the latest milestone for the Morphic Medical business.

Following recent CE Mark certification and commercial registration by the UK’s MHRA, RESET® is cleared for sale across key European markets, including Germany where rollout has already begun. In her new role, Wright will play a key role in shaping the company’s long-term financial strategy and supporting its continued growth.

Research presented to the IFSO World Congress of obesity experts this month has shown that RESET® delivers substantial and durable benefits, with patients losing an average of 18.9% of their total body weight, while also improving blood sugar control.

Mike Gutteridge, President & Chief Executive Officer of Morphic Medical, commented: “We are thrilled to welcome Jane to our executive team. Her extensive expertise and deep knowledge of the sector makes her a real asset to Morphic as the momentum within the business continues to build.”

Jane Wright, Chief Financial Officer of Morphic Medical, commented: “I’m joining Morphic Medical at an exciting time in its growth journey. I look forward to working closely with the leadership team to help take the business to the next level.”

ABOUT MORPHIC MEDICAL

Morphic Medical is the developer of RESET®, the first endoscopic, non-surgical treatment for both obesity and type 2 diabetes in Europe. The business is 97% owned by Crystal Amber Fund Ltd, listed on the UK AIM market.

RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine, it has been shown to support significant weight loss and improved blood sugar control by enhancing natural gut hormone responses, in a way similar to GLP-1 therapies. Unlike gastric bypass surgery, RESET is minimally invasive and fully reversible.

RESET addresses a major global health need, with an estimated 93 million adults in Europe alone living with obesity and type 2 diabetes. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts. For more information, please visit morphicmedical.com or follow us on X (formerly Twitter) and / or LinkedIn.